SCHEMBL30401899

SCHEMBL30401899

CN(C)c1nc2ncncc2s1

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.38
EGFR P00533 2/20 0.35
LMNA P02545 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL813862 0.75 SMN1; SMN2 (0.39)
SCHEMBL31167726 0.72 EGFR (0.30) EGFR
SCHEMBL30402699 0.71 PDPK1 (0.36) EGFR
SCHEMBL13472688 0.71
SCHEMBL12210434 0.70
SCHEMBL30808059 0.68 IKBKB (0.31)
SCHEMBL21823121 0.67 AXL (0.35) HTTEGFR
SCHEMBL23458477 0.64 KDM4E (0.49)
SCHEMBL4512720 0.63 HTT (0.63) HTTLMNACYP1A2CYP2D6
SCHEMBL10994146 0.63 HTT (0.49) HTTLMNACYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4430022-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE Vigil Neuroscience, Inc. (US) 2024-09-18 EP disclosed
WO-2023086801-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2023-05-19 WO disclosed